The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.

Jun YangChao HuangShanshan WuYang XuTing CaiSanbao ChaiZhirong YangFeng SunSiyan Zhan

Published in: PloS one (2017)

Alogliptin may be associated with a lower risk of bone fracture compared with placebo, linagliptin, or saxagliptin, while other anti-diabetes did not seem to have an association with the risk of bone fracture.

Keyphrases

bone mineral density
soft tissue
type diabetes
bone loss
bone regeneration
glycemic control
hip fracture
cardiovascular disease
postmenopausal women
randomized controlled trial
clinical trial
metabolic syndrome